1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,627 | 0,667 | 24.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital | 367 | Business Wire | Article 223-16 du Règlement Général de l'Autorité des marchés financiers
Regulatory News:
Theraclion (Paris:ALTHE):
Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code: FR0010120402
Website:... ► Artikel lesen | |
| 23.07. | Theraclion Initiates Its Commercial Momentum in the First Half of 2026 | 501 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused... ► Artikel lesen | |
| 15.07. | Theraclion: First Half 2026 Report on the Liquidity Contract With CRÉDIT INDUSTRIEL ET COMMERCIAL | 380 | Business Wire | Regulatory News:
Theraclion (Paris:ALTHE):
Listing venue: Euronext Growth Paris
PEA-PME eligible
ISIN Code: FR0010120402
Website: www.theraclion.com
Under the liquidity contract entrusted... ► Artikel lesen | |
| 09.07. | Theraclion Strengthens Its Governance by Appointing Vincent Gardès as Chairman of Its Board of Directors | 431 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused... ► Artikel lesen | |
| 02.07. | Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital | 370 | Business Wire | Article 223-16 Règlement Général de l'Autorité des marchés financiers
Regulatory News:
Theraclion (Paris:ALTHE):
Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code: FR0010120402
Website:... ► Artikel lesen | |
| 18.06. | Theraclion Announces the Evolution of Its Board of Directors | 883 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused... ► Artikel lesen | |
| 08.06. | Theraclion Secures Key U.S. Reimbursement Milestone for Sonovein With AMA CPT Editorial Panel Approval of a New Category III CPT Code | 421 | Business Wire | Regulatory News:
Theraclion (ISIN: FR0010120402; Ticker: ALTHE), an innovative company developing a platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the treatment... ► Artikel lesen | |
| THERACLION Aktie jetzt für 0€ handeln | |||||
| 04.06. | Theraclion Announces First Clinical Deployment of Sonovein in Hainan, China | 476 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402 Mnemo: ALTHE), an innovative company developing a robotic platform for non-invasive therapy using high intensity focused ultrasound (HIFU) for the... ► Artikel lesen | |
| 03.06. | Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital | 379 | Business Wire | Article 223-16 du Règlement Général de l'Autorité des marchés financiers
Regulatory News:
Theraclion (Paris:ALTHE):
Listed on Euronext Growth Paris
PEA PME eligible
ISIN Code: FR0010120402
Website:... ► Artikel lesen | |
| 01.06. | Theraclion Announces the Success of the First International HIFU Congress in Parma, Where Promising Preliminary Results From Its Sonovein SpeedPulse Were Presented | 422 | Business Wire | Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260601718811/en/Illustration of Sonovein with new robotics SpeedPulse
Theraclion... ► Artikel lesen | |
| 11.05. | Theraclion Announces the Strong Success of Its Oversubscribed Capital Increase | 461 | Business Wire | Capital increase of a gross amount of 6 million Issue of 12,484,467 BSA enabling an additional fundraising of 2 million
Regulatory News:
This press release and the information it contains... ► Artikel lesen | |
| 28.04. | Theraclion's non-invasive varicose treatment poised for FDA decision | 2 | The Armchair Trader | ||
| 23.04. | XFRA NEW INSTRUMENTS AVAILABLE ON 23.04.2026 | 548 | Xetra Newsboard | The following instruments on XETRA do have their first trading 23.04.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.04.2026
Aktien
1 ID1000132806 PT Multi Bintang Indonesia... ► Artikel lesen | |
| 20.04. | Theraclion Announces the Launch of a Capital Increase Through the Issuance of ABSA (Shares With Share Warrants Attached), With Preferential Subscription Rights for Existing Shareholders, for a Gross Amount of €6 Million, Secured by Subscription... | 801 | Business Wire | Subscription price: €0.48 per share, representing a nominal discount of 3.52% to the closing share price as of April 17, 2026, and a discount of 8.60% when taking into account the theoretical... ► Artikel lesen | |
| 16.04. | Theraclion Publishes Its 2025 Financial Results and Provides an Update on Its Outlook | 636 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose... ► Artikel lesen | |
| 29.01. | Theraclion Delivers a Structuring Year in 2025 and Prepares to Scale up | 499 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose... ► Artikel lesen | |
| 09.12.25 | Theraclion Announces Sonovein FDA Submission Following a Strong Year of Regulatory and Clinical Achievements | 748 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose... ► Artikel lesen | |
| 29.10.25 | Theraclion Reports Major Recent Developments and Announces Its 2025 Half-Year Financial Results | 616 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose... ► Artikel lesen | |
| 21.10.25 | Theraclion Secures Key Chinese Certification, Advancing Toward Market Access in China | 462 | Business Wire | Regulatory News:
THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive High-Intensity Focused Ultrasound (HIFU) varicose... ► Artikel lesen | |
| 10.10.25 | Theraclion: Monthly Information on the Total Number of Voting Rights and Shares Comprising the Share Capital | 534 | Business Wire | Article 223-16 du Règlement Général de l'Autorité des marchés financiers
Regulatory News:
Theraclion (Paris:ALTHE):
Place de cotation: Euronext Growth Paris
Éligible PEA PME
Code ISIN:... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GERRESHEIMER | 28,020 | +1,52 % | Gerresheimer verliert Interim-Chef früher als geplant: Gerresheimer Aktie im Blick Uwe Röhrhoff beendet Interim-CEO-Mandat vorzeitig | Bei Gerresheimer kommt es früher als geplant zu einem Wechsel an der Konzernspitze. Interim-CEO Uwe Röhrhoff hat sein Mandat auf eigenen Wunsch vorzeitig beendet.Röhrhoff geht vor geplantem Ablauf Die... ► Artikel lesen | |
| MCKESSON | 743,60 | -0,77 % | Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation? | ||
| INMODE | 12,620 | -2,51 % | InMode Ltd.: InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025 | YOKNEAM, Israel, Aug. 5, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced... ► Artikel lesen | |
| HCA HEALTHCARE | 368,10 | 0,00 % | ROUNDUP: HCA Healthcare Trims FY26 EPS Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Friday, HCA Healthcare, Inc. (HCA) trimmed its earnings guidance for the full-year 2026, while narrowing its... ► Artikel lesen | |
| LIMES SCHLOSSKLINIKEN | 575,00 | 0,00 % | EQS-DD: Limes Schlosskliniken AG: Henri B.F. Bennert, Verkauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
10.08.2026 / 08:26... ► Artikel lesen | |
| BEYOND AIR | 4,910 | 0,00 % | Beyond Air, Inc. - 8-K, Current Report | ||
| HEALTHCARE SERVICES GROUP | 19,400 | 0,00 % | HEALTHCARE SERVICES GROUP INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| ADDUS HOMECARE | 101,00 | 0,00 % | Addus HomeCare replaces COO Heather Dixon with interim return of Brad Bickham | ||
| INTERPACE BIOSCIENCES | 1,330 | -5,67 % | INTERPACE BIOSCIENCES, INC. - 8-K, Current Report | ||
| MYOMO | 1,198 | +0,84 % | Myomo expects $45M-$47M full-year revenue while targeting second-half cash burn below $2M | ||
| MODERN DENTAL | 0,895 | -2,72 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2026 | Das Instrument 7V3 SE0006371126 CANTARGIA AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.06.2026 The instrument 7V3 SE0006371126 CANTARGIA AB EQUITY is traded ex capital adjustment on 03.06.2026Das... ► Artikel lesen | |
| IVF HARTMANN | 138,00 | 0,00 % | IVF Hartmann erwirtschaftet im Halbjahr klar mehr Umsatz | Neuhausen am Rheinfall - Der Medizinalbedarf-Hersteller IVF Hartmann hat im ersten Halbjahr 2026 den Umsatz zweistellig gesteigert. Der Gewinn nahm im Vergleich dazu noch deutlicher zu. Die Prognose... ► Artikel lesen | |
| ICU MEDICAL | 156,00 | 0,00 % | Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 29, 2026, driven by key catalysts such as the release of second quarter financial results and ongoing clinical... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,300 | +0,40 % | EQS-News: Fresenius SE & Co. KGaA: Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen Euro | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Beteiligung/Unternehmensbeteiligung
Fresenius verkauft 7,8 Millionen Fresenius Medical Care-Aktien im Wert von rund 300 Millionen... ► Artikel lesen | |
| FRESENIUS | 46,040 | -1,20 % | Fresenius verkauft FMC-Paket - das müssen Anleger wissen |
THERACLION SA gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,608 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THERACLION SA finden Sie auf Wallstreet Online.